Collaboration
← Earnings Calls
01
02
03
04 05 06
Tone
Capex
A1 A2 A3
REGN
FY2026 Q2
Improving
Regeneron Pharmaceuticals, Inc. earnings call
Buzzberg read
Sanofi collaboration repayment complete, boosting revenue from Q3.
Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo.
Buzzberg read Sanofi collaboration repayment complete, boosting revenue from Q3. Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo. Read full analysisCollapse analysis
Regeneron's Q2 2026 results showed strong growth driven by Dupixent, Eylea HD, and Libtayo, with a positive outlook and new pipeline catalysts. Management discusses early M&A interest and successful collaboration with Sanofi. FY2026 2Q revenue grew 17% to $4.3 billion driven by Dupixent, Eylea HD, and Libtayo.
- Dupixent net sales reached $6 billion, up 38%, with Eylea HD up 52% to $596 million.
- Libtayo net sales up 29% to $489 million, capturing 20% of new-to-brand lung cancer share.
- CFO notes full Sanofi development balance repayment will boost Sanofi collaboration revenue from Q3 onwards.
Revenue$4.2907B+19% QoQ
EPS$14.29+51% QoQ
Gross margin86.56%Reported
Operating margin33.11%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Regulatory
ILEA-HD pre-filled syringe approval targeted by year-end.
Pipeline
Long-acting IL-13 antibody shows prolonged half-life, expedited path.
Show 3 more callouts
Partnerships
Discussions with Sanofi to expand collaboration on follow-on assets.
Obesity
Obesity portfolio advancing with Phase III starts expected.
Pipeline
Factor XI program to initiate remaining Phase III studies this year.
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $4.2907B | +19% QoQ |
| EPS | $14.29 | +51% QoQ |
| Gross margin | 86.56% | Reported |
| Operating margin | 33.11% | Reported |
| Free cash flow | $0.3343B | Reported |
| Capex | $0.2402B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| Free cash flow | FY2026 | $1.4B | $1.4B | Guided |
AI, capex & demand read
Management read
Upbeat
Management highlighted strong growth across key products, reiterated confidence in the pipeline and partnerships, and emphasized a broad, diversified portfolio and disciplined capital allocation.
Investment and capacity
The company noted a temporary interruption in bulk manufacturing production at its Limerick, Ireland facility, which resumed to normal levels as of the end of the second quarter. No other significant capital expenditure or capacity investment details were discussed.
all 2 named companies below
Companiesreturns since call
Partners
Partners
Chris Fenimore
Bayesian product royalties and profit share contributed a significant increase to other revenue, indicating underlying strength from the Bayer collaboration's portfolio.
Evidence
“royalty income from Alaris combined with our share of profits from Arculus totaled $157 million, an increase of 44% versus the prior year.”
Partners
Dr. Leonard Schleifer
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits. — A new, higher-margin, recurring profit share kicks in following the repayment.
Evidence
“productive early discussions with Sanofi to identify potential opportunities for further collaboration, including for several of Regeneron's Depixent follow-on programs.”
External signals
Supply-chain alpha · 3returns since call
The full repayment of the Sanofi development balance will boost Sanofi collaboration revenue from Q3 onwards, with the company recording its full share of collaboration profits.
Evidence
“Given full repayment of the Sanofi development balance, Starting in the third quarter, we expect Sanopi Collaboration Revenue to step up as we record our full share of collaboration profits.”
After two consecutive quarters of pressure, Regeneron's Limerick facility resumed normal production levels, alleviating unabsorbed manufacturing costs.
Evidence
“Production at this facility resumed to normal levels as of the end of the second quarter.”
ILI-A HD sequentially declined 13-15% due to conversions and biosimilars, while HD is expected to grow low-to-mid teens on the back of share gains.
Evidence
“we expect sequential quarterly demand declines in the low to mid-teens due to the factors mentioned as well as additional competition primarily from multiple Flippercept 2 mg biosimilar launches.”
Methodology & coverage
Management-only analysis. All 2 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.